We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Tesla, Comcast, AbbVie, Boeing, China Petroleum & Chemical and Advanced Micro Devices
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 8, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tesla, Inc. (TSLA - Free Report) , Comcast Corporation (CMCSA - Free Report) , AbbVie Inc. (ABBV - Free Report) , The Boeing Company (BA - Free Report) , China Petroleum & Chemical Corporation and Advanced Micro Devices, Inc. (AMD - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Tesla, Comcast and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA - Free Report) , Comcast (CMCSA - Free Report) , and AbbVie Inc. (ABBV - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Tesla have outperformed the Zacks Automotive – Domestic industry over the year-to-date period (+74.3% vs. +46.7%). The electric vehicle (EV) king hit a milestone in third-quarter 2021, with gross auto margins attaining a record high. The Zacks analyst believes that riding on robust Model 3/Y demand, Tesla achieved record Q3 production and deliveries despite chip crunch. The company has also started making progress at ramping up volumes of Models S and X.
With China being the biggest EV market, Tesla’s Shanghai factory is buoying the company's revenue prospects. Also, production from Berlin and Texas gigafactories is expected to commence this year. In addition to increasing automotive revenues, Tesla’s energy generation and storage revenues are also boosting earnings prospects.
Shares of Comcast have underperformed the Zacks Cable Television industry over the year-to-date period (+0.6% vs. +2.8%). The Zacks analyst believes that Comcast is benefiting from strength in broadband subscriber base and a strong momentum in wireless business besides advertising revenue growth as reflected by third-quarter 2021 results.
Its strategy to provide high-speed Internet at an affordable price plays a pivotal role in providing connectivity, improving customer wins and experience. Moreover, coronavirus-led increased media consumption, and the work-from-home and online-learning wave bode well for Comcast’s Internet business. However, Comcast persistently suffers from video-subscriber attrition due to cord cutting. Moreover, a leveraged balance sheet is a major concern.
Shares of AbbVie have underperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+9.3% vs. +17.3%). Nonetheless, AbbVie beat estimates for Q3 earnings while missing for sales. The Zacks analyst believes that AbbVie has been successful in expanding the labels of its cancer drugs, Imbruvica and Venclexta. It has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. exclusivity in 2023. It has an impressive late-stage pipeline with several early/mid-stage candidates that have blockbuster potential.
However, the FDA’s order to include a heart-risk warning in the label of JAK inhibitor drug, Rinvoq may hurt the drug’s sales in the future quarters. There are concerns about long-term sales growth once Humira generics enter the U.S. market.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Tesla, Comcast, AbbVie, Boeing, China Petroleum & Chemical and Advanced Micro Devices
For Immediate Release
Chicago, IL – November 8, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tesla, Inc. (TSLA - Free Report) , Comcast Corporation (CMCSA - Free Report) , AbbVie Inc. (ABBV - Free Report) , The Boeing Company (BA - Free Report) , China Petroleum & Chemical Corporation and Advanced Micro Devices, Inc. (AMD - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Tesla, Comcast and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA - Free Report) , Comcast (CMCSA - Free Report) , and AbbVie Inc. (ABBV - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Tesla have outperformed the Zacks Automotive – Domestic industry over the year-to-date period (+74.3% vs. +46.7%). The electric vehicle (EV) king hit a milestone in third-quarter 2021, with gross auto margins attaining a record high. The Zacks analyst believes that riding on robust Model 3/Y demand, Tesla achieved record Q3 production and deliveries despite chip crunch. The company has also started making progress at ramping up volumes of Models S and X.
With China being the biggest EV market, Tesla’s Shanghai factory is buoying the company's revenue prospects. Also, production from Berlin and Texas gigafactories is expected to commence this year. In addition to increasing automotive revenues, Tesla’s energy generation and storage revenues are also boosting earnings prospects.
(You can read the full research report on Tesla here >>>)
Shares of Comcast have underperformed the Zacks Cable Television industry over the year-to-date period (+0.6% vs. +2.8%). The Zacks analyst believes that Comcast is benefiting from strength in broadband subscriber base and a strong momentum in wireless business besides advertising revenue growth as reflected by third-quarter 2021 results.
Its strategy to provide high-speed Internet at an affordable price plays a pivotal role in providing connectivity, improving customer wins and experience. Moreover, coronavirus-led increased media consumption, and the work-from-home and online-learning wave bode well for Comcast’s Internet business. However, Comcast persistently suffers from video-subscriber attrition due to cord cutting. Moreover, a leveraged balance sheet is a major concern.
(You can read the full research report on Comcast here >>>)
Shares of AbbVie have underperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+9.3% vs. +17.3%). Nonetheless, AbbVie beat estimates for Q3 earnings while missing for sales. The Zacks analyst believes that AbbVie has been successful in expanding the labels of its cancer drugs, Imbruvica and Venclexta. It has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. exclusivity in 2023. It has an impressive late-stage pipeline with several early/mid-stage candidates that have blockbuster potential.
However, the FDA’s order to include a heart-risk warning in the label of JAK inhibitor drug, Rinvoq may hurt the drug’s sales in the future quarters. There are concerns about long-term sales growth once Humira generics enter the U.S. market.
(You can read the full research report on AbbVie here >>>)
Other noteworthy reports we are featuring today include Boeing, China Petroleum & Chemical and Advanced Micro Devices.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.